MESOPOROUS SILICA for Drug Delivery

increased solubility
taste masking
controlled release
stability boost
bioequivalence

NLAB Silica

Sharp pore size	2-20 nm
High surface area	> 900 m^2/g
Large pore volume	> 0.7 cm^3/g
Controlled particle size	0,3-50 µm
Tailored connectivity	2D-3D
High loading	> 45 wt%

NEW technology

INORGANIC, SAFE & BIOCOMPATIBLE excipients

SCALABLE production

LIFE-CYCLE EXTENSION

Reformulation of marketed drugs with soon to expire patents allows to create improved products and extend their period of exclusivity.



GENERICS

Achieving bioequivalence of reference products with protected formulations is possible thanks to our proprietary technology.

Solubilisation of hydrophobic candidates.

Ready to market pre-formulation.

PIPELINE EXPANSION

From parental to oral. Encapsulation of API in porous silica allows to protect API for oral administration.

NEW THERAPIES

plus

DRUG+

For drugs with expired API patent but highly protected formulations our technology offers easy to obtain bioequivalence.

Time to market
2-3 years

PIPELINE+

For poorly soluble candidates our technology ensures high solubility and bioavailability.

Time to market
following the APIs track/ time line

GENERICS+

For drugs on the market whose patent is close to expiring we offer an easy route for improvement and patent extension with our proprietary technology.

Time to market
2-3 years

BIOVAILABILITY ENHANCEMENT



Sprague Dawley rats were administered with Omeprazole (100 mg/kg) 5 hours prior to the administration of free Atazanavir and NLAB Silica loaded with Atazanavir (10 mg/kg)

NANOLOGICA™
ENGINEERED NANOMATERIALS